2026-07507NoticeWallet

FDA Updates Paperwork for Radioactive Drug Studies

Published Date: 4/17/2026

Notice

Summary

The FDA wants your thoughts on how they collect info about radioactive drug research committees. This affects researchers using radioactive drugs for basic studies and aims to keep paperwork clear and up-to-date. You’ve got until June 16, 2026, to share your comments—no extra costs, just your voice!

Free Policy Watch

New rules are filed every week. Most people never see them.

Pick a topic. PRIA watches every federal rule and tells you when one hits your household.

Pick a topic to get started

Analyzed Economic Effects

4 provisions identified: 2 benefits, 2 costs, 0 mixed.

FDA Authorization Required First

If you conduct basic human research using radioactive drugs, you cannot give those drugs to people unless an FDA-approved Radioactive Drug Research Committee (RDRC) authorizes the study under 21 CFR 361.1(d)(7). Studies under RDRC must be basic research (for example, studies of metabolism or human physiology) and not clinical trials for safety or effectiveness; clinical trials require filing an IND under 21 CFR part 312.

Reporting and Recordkeeping Burden

RDRC chairs and investigators must keep minutes, meet at least quarterly when activity occurs, and submit annual reports using Form FDA 2914 (Membership Summary) and Form FDA 2915 (Study Summary). FDA estimates annual reporting at 1,194 hours total and annual recordkeeping at 2,443 hours total (combined 3,637 hours), and notes an overall decrease of 52 hours and 97 responses versus prior estimates.

Consent and Pregnancy Testing Rules

Investigators must obtain the required informed consent from research subjects, and every female subject of childbearing potential must either state in writing that she is not pregnant or be confirmed not pregnant by a pregnancy test under 21 CFR 361.1(d)(5).

Adverse Event Reporting Requirement

Investigators must immediately report all adverse effects associated with the radioactive drug to the RDRC, and the RDRC must report to FDA adverse reactions probably attributed to the drug under 21 CFR 361.1(d)(8).

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Comments Due
4/17/2026
6/16/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in